Rethinking schizophrenia

How will we view schizophrenia in 2030? Schizophrenia today is a chronic, frequently disabling mental disorder that affects about one per cent of the world’s population. After a century of studying schizophrenia, the cause of the disorder remains unknown. Treatments, especially pharmacological treatments, have been in wide use for nearly half a century, yet there is little evidence that these treatments have substantially improved outcomes for most people with schizophrenia. These current unsatisfactory outcomes may change as we approach schizophrenia as a neurodevelopmental disorder with psychosis as a late, potentially preventable stage of the illness. This ‘rethinking’ of schizophrenia as a neurodevelopmental disorder, which is profoundly different from the way we have seen this illness for the past century, yields new hope for prevention and cure over the next two decades.

[1]  A. Minkowski,et al.  Regional Development of the Brain in Early Life , 1968 .

[2]  I. Feinberg,et al.  Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? , 1982, Journal of psychiatric research.

[3]  Barbara A. Cornblatt,et al.  The New York High-Risk Project. , 1984 .

[4]  P. Huttenlocher Synapse elimination and plasticity in developing human cerebral cortex. , 1984, American journal of mental deficiency.

[5]  P. Goldman-Rakic,et al.  Concurrent overproduction of synapses in diverse regions of the primate cerebral cortex. , 1986, Science.

[6]  S. Kety,et al.  The significance of genetic factors in the etiology of schizophrenia: results from the national study of adoptees in Denmark. , 1987, Journal of psychiatric research.

[7]  D. Weinberger Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[8]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[9]  Where next with psychiatric illness? , 1988, Nature.

[10]  G. Reynolds,et al.  Beyond the Dopamine Hypothesis , 1989, British Journal of Psychiatry.

[11]  R. Murray,et al.  Fetal brain development and later schizophrenia. , 1991, Ciba Foundation symposium.

[12]  E. Susser,et al.  Schizophrenia after prenatal exposure to the Dutch hunger winter of 1944–1945 , 1993, Schizophrenia Research.

[13]  C. Waternaux,et al.  One hundred years of schizophrenia: A meta-analysis of the outcome literature , 1993, Schizophrenia Research.

[14]  M. Tohen,et al.  One hundred years of schizophrenia: a meta-analysis of the outcome literature. , 1994 .

[15]  Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944-1945. , 1994 .

[16]  D. Rosenberg,et al.  Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: A tyrosine hydroxylase immunohistochemical analysis , 1995, The Journal of comparative neurology.

[17]  Paul J. Harrison Schizophrenia: a disorder of neurodevelopment? , 1997, Current Opinion in Neurobiology.

[18]  R. Murray,et al.  Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. , 1999, Archives of general psychiatry.

[19]  G Benedetti,et al.  Interpretation of schizophrenia. , 1999, The Journal of the American Academy of Psychoanalysis.

[20]  J. Rapoport,et al.  Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. , 1999, Archives of general psychiatry.

[21]  J. Cohen,et al.  Context-processing deficits in schizophrenia: converging evidence from three theoretically motivated cognitive tasks. , 1999, Journal of abnormal psychology.

[22]  B. Cornblatt,et al.  Cognitive and behavioral precursors of schizophrenia , 1999, Development and Psychopathology.

[23]  P. Goldman-Rakic,et al.  Differential Postnatal Development of Catecholamine and Serotonin Inputs to Identified Neurons in Prefrontal Cortex of Rhesus Monkey , 2000, The Journal of Neuroscience.

[24]  Tyrone D. Cannon,et al.  Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study. , 2000, Schizophrenia bulletin.

[25]  I. Gottesman,et al.  Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project. , 2000, The American journal of psychiatry.

[26]  R. Buchanan,et al.  A separate disease within the syndrome of schizophrenia. , 2001, Archives of general psychiatry.

[27]  E. Laska,et al.  Recovery from psychotic illness: A 15- and 25-year international follow-up study , 2001, British Journal of Psychiatry.

[28]  Peter B. Jones,et al.  Obstetric complications and schizophrenia: historical and meta-analytic review. , 2002, The American journal of psychiatry.

[29]  Judith A. Hall,et al.  A Meta-analytic Review , 2002 .

[30]  R. Straub,et al.  Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. , 2002, American journal of human genetics.

[31]  S. Hyman,et al.  Medicine. What are the right targets for psychopharmacology? , 2003, Science.

[32]  T. McGlashan,et al.  Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome , 2003, Biological Psychiatry.

[33]  S. Hyman,et al.  What Are the Right Targets for Psychopharmacology? , 2003, Science.

[34]  Rosanna Weksberg,et al.  The schizophrenia phenotype in 22q11 deletion syndrome. , 2003, The American journal of psychiatry.

[35]  Robert M Bilder,et al.  Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. , 2004, The American journal of psychiatry.

[36]  R. Bentall,et al.  Cognitive therapy for the prevention of psychosis in people at ultra-high risk , 2004, British Journal of Psychiatry.

[37]  Thomas F. Nugent,et al.  Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood-onset atypical psychoses. , 2004, Archives of general psychiatry.

[38]  Abdulmajeed Al Abdukareem Randomized, placebo-controlled trial , 2004, Annals of Saudi medicine.

[39]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[40]  P. Sham,et al.  Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. , 2005, JAMA.

[41]  Michael F. Green,et al.  A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. , 2005, Schizophrenia bulletin.

[42]  Jürgen Unützer,et al.  Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. , 2005, The American journal of psychiatry.

[43]  J. Lieberman,et al.  Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III , 2005, Schizophrenia Research.

[44]  Craig W. Colton,et al.  Congruencies in Increased Mortality Rates, Years of Potential Life Lost, and Causes of Death Among Public Mental Health Clients in Eight States , 2006, Preventing chronic disease.

[45]  Karin E. Borgmann-Winter,et al.  Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.

[46]  Brian Kirkpatrick,et al.  The NIMH-MATRICS consensus statement on negative symptoms. , 2006, Schizophrenia bulletin.

[47]  A. Bassett,et al.  Neurocognitive profile in 22q11 deletion syndrome and schizophrenia , 2006, Schizophrenia Research.

[48]  J. Coyle,et al.  Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis , 2006, Cellular and Molecular Neurobiology.

[49]  J. Lieberman,et al.  Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. , 2007, The American journal of psychiatry.

[50]  Paul J. Harrison,et al.  Molecular Cloning of a Brain-specific, Developmentally Regulated Neuregulin 1 (NRG1) Isoform and Identification of a Functional Promoter Variant Associated with Schizophrenia*♦ , 2007, Journal of Biological Chemistry.

[51]  Alcino J. Silva,et al.  Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice , 2007, Proceedings of the National Academy of Sciences.

[52]  M. Berk,et al.  Neuroprotection in emerging psychotic disorders , 2007 .

[53]  C. Correll,et al.  Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. , 2007, The Journal of clinical psychiatry.

[54]  Mondher Toumi,et al.  Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. , 2007, The British journal of psychiatry : the journal of mental science.

[55]  J. Lieberman,et al.  Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. , 2007, The American journal of psychiatry.

[56]  Tyrone D. Cannon,et al.  Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. , 2008, Archives of general psychiatry.

[57]  A. Bechdolf,et al.  Back to the future: predicting and reshaping the course of psychotic disorder. , 2008, Archives of general psychiatry.

[58]  Bruce E. Wexler,et al.  Neurocognitive enhancement therapy with vocational services: Work outcomes at two-year follow-up , 2008, Schizophrenia Research.

[59]  S. Petersen,et al.  The maturing architecture of the brain's default network , 2008, Proceedings of the National Academy of Sciences.

[60]  Larry J Seidman,et al.  Premorbid IQ in schizophrenia: a meta-analytic review. , 2008, The American journal of psychiatry.

[61]  Paul Pavlidis,et al.  Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model , 2008, Nature Genetics.

[62]  Carlo Colantuoni,et al.  Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex , 2008, Brain Structure and Function.

[63]  T. Paus,et al.  Why do many psychiatric disorders emerge during adolescence? , 2008, Nature Reviews Neuroscience.

[64]  Joseph A. Gogos,et al.  Palmitoylation-dependent neurodevelopmental deficits in a mouse model of the 22q11 microdeletion , 2008, Nature Neuroscience.

[65]  S Marenco,et al.  Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk , 2008, Molecular Psychiatry.

[66]  A. Bechdolf,et al.  Validation of “prodromal” criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up , 2008, Schizophrenia Research.

[67]  D. Lewis,et al.  Neuroplasticity of Neocortical Circuits in Schizophrenia , 2008, Neuropsychopharmacology.

[68]  A. Singleton,et al.  Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia , 2008, Science.

[69]  Laurence Faivre,et al.  Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. , 2009, Archives of general psychiatry.

[70]  J. Mukai,et al.  Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion , 2009, Neuroscience Research.

[71]  W. Fenton,et al.  Suicide rate in schizophrenia in the Northern Finland 1966 Birth Cohort , 2009, Social Psychiatry and Psychiatric Epidemiology.

[72]  David B. Goldstein,et al.  A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia , 2009, PLoS genetics.

[73]  M. Cuccaro,et al.  Genomic and epigenetic evidence for oxytocin receptor deficiency in autism , 2009, BMC medicine.

[74]  K. Takemura,et al.  Impact of changing the Japanese term for “schizophrenia” for reasons of stereotypical beliefs of schizophrenia in Japanese youth , 2009, Schizophrenia Research.

[75]  R. Vakkalanka,et al.  DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms , 2009, Proceedings of the National Academy of Sciences.

[76]  Akira Sawa,et al.  Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1–ErbB4 and DISC1 , 2009, Trends in Neurosciences.

[77]  Tyrone D. Cannon,et al.  Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. , 2009, Schizophrenia bulletin.

[78]  P. Visscher,et al.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.

[79]  Pall I. Olason,et al.  Common variants conferring risk of schizophrenia , 2009, Nature.

[80]  Takanori Hashimoto,et al.  Protracted Developmental Trajectories of GABA A Receptor α1 and α2 Subunit Expression in Primate Prefrontal Cortex , 2009, Biological Psychiatry.

[81]  Elvira Bramon,et al.  Disruption of the neurexin 1 gene is associated with schizophrenia. , 2009, Human molecular genetics.

[82]  Akira Sawa,et al.  Understanding the Role of DISC1 in Psychiatric Disease and during Normal Development , 2009, The Journal of Neuroscience.

[83]  Deanna M Barch,et al.  CNTRICS final task selection: social cognitive and affective neuroscience-based measures. , 2009, Schizophrenia bulletin.

[84]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[85]  U. Gschwandtner,et al.  Efficacy of Using Cognitive Status in Predicting Psychosis: A 7-Year Follow-Up , 2009, Biological Psychiatry.

[86]  Stephen W Scherer,et al.  Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. , 2010, The American journal of psychiatry.

[87]  M. King,et al.  Genetic Heterogeneity in Human Disease , 2010, Cell.

[88]  P. Mcguire,et al.  Neuroimaging predictors of transition to psychosis—A systematic review and meta-analysis , 2010, Neuroscience & Biobehavioral Reviews.

[89]  E. Bleuler [Dementia praecox or the group of schizophrenias]. , 1968, Vertex.

[90]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[91]  S. Hyman,et al.  Animal models of neuropsychiatric disorders , 2010, Nature Neuroscience.

[92]  P. Levitt,et al.  Now You See It, Now You Don't—Closing in on Allostasis and Developmental Basis of Psychiatric Disorders , 2010, Neuron.

[93]  J. Suvisaari [Risk factors of schizophrenia]. , 2010, Duodecim; laaketieteellinen aikakauskirja.

[94]  A. Mackinnon,et al.  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. , 2010, Archives of general psychiatry.

[95]  NEUROPSYCHOLOGY OF THE PRODROME TO PSYCHOSIS IN THE NAPLS CONSORTIUM: RELATIONSHIP TO FAMILY HISTORY AND CONVERSION TO PSYCHOSIS , 2008, Schizophrenia Research.

[96]  H. Yuen,et al.  The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission. , 2010, The Journal of clinical psychiatry.

[97]  Philip D. Harvey,et al.  The Course of Neuropsychological Performance and Functional Capacity in Older Patients with Schizophrenia: Influences of Previous History of Long-Term Institutional Stay , 2010, Biological Psychiatry.

[98]  A. Feinberg,et al.  Stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease , 2010, Proceedings of the National Academy of Sciences.

[99]  J. Schiffman,et al.  Early developmental milestones and risk of schizophrenia: A 45-year follow-up of the Copenhagen Perinatal Cohort , 2010, Schizophrenia Research.

[100]  A. Gruber,et al.  Knockdown of DISC1 by In Utero Gene Transfer Disturbs Postnatal Dopaminergic Maturation in the Frontal Cortex and Leads to Adult Behavioral Deficits , 2010, Neuron.

[101]  Alan S. Brown,et al.  Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. , 2010, The American journal of psychiatry.

[102]  Richie Poulton,et al.  Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. , 2010, The American journal of psychiatry.

[103]  Tony J. Simon,et al.  22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia , 2010, Nature Reviews Neuroscience.

[104]  Alan S. Brown,et al.  Cognitive decline in schizophrenia from childhood to midlife: A 33-year longitudinal birth cohort study , 2010, Schizophrenia Research.

[105]  W. Tsai,et al.  Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8 , 2010, Schizophrenia Research.

[106]  D. Kelly,et al.  Cigarette smoking and mortality risk in people with schizophrenia. , 2011, Schizophrenia bulletin.

[107]  S. Silverstein,et al.  Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. , 2011, Schizophrenia bulletin.

[108]  R. Murray,et al.  Prefrontal and striatal volumes in monozygotic twins concordant and discordant for schizophrenia. , 2012, Schizophrenia bulletin.